House of Lords Business
Show full summary

Lord Hunt of Kings Heath to ask Her Majesty's Government what discussions they have held, if any, with the National Institute for Health and Care Excellence (NICE) in relation to the delay in its committee meeting to discuss the use of the drug Trodelvy (sacituzumab govitecan) for certain patients living with triple negative secondary breast cancer.  HL149

Question HL149: tabled on 11 May 2022 and due for answer by 25 May 2022

This type of business sits within the Questions & Statements category.

This question has been answered by the relevant Government Department.

Question text

Lord Hunt of Kings Heath to ask Her Majesty's Government what discussions they have held, if any, with the National Institute for Health and Care Excellence (NICE) in relation to the delay in its committee meeting to discuss the use of the drug Trodelvy (sacituzumab govitecan) for certain patients living with triple negative secondary breast cancer.  HL149
Legend for business item text
† Item that is new or altered.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Member's Registered Interests

There are no interests to show.

Main Member

Lord Hunt of Kings Heath
Labour
Life peer